BodyLogicMD brings together several kinds of information: a menopause-care offer, a clinician directory, testing descriptions and an Advantage membership. None is the same thing as a finished medicine label. For a reader interested in micronized progesterone, the main task is to avoid turning the network’s overall language into a claim about every participating clinician’s prescriptions.
We reviewed BodyLogicMD’s menopause, directory and pricing pages on September 29, 2026. The service is relevant to a hormone-care consultation, but its public network identity does not verify a particular capsule, manufacturer, pharmacy or route. This review follows the documents from the broadest description toward the missing product details, including the distinction between a membership payment and treatment costs.
Read this article by section
Start with the clinician behind the network listing
The menopause page describes hormone evaluation and treatment, and the directory provides a way to identify practices. Together they establish more than an educational article. They do not show that every clinician has identical availability, prescribing preferences or arrangements with pharmacies. A useful first inquiry names the intended clinician and location, then asks whether that practice can assess the relevant concern. Our Defy Medical review approaches a broad hormone menu from another care model. The difference between a network and a single service description matters operationally without implying a difference in treatment quality. The directory is also distinct from a product manufacturer’s record. A clinician’s listing can help locate the practice responsible for assessment, but it does not certify the composition of a medicine later supplied by another organization. When contacting a listed practice, keep the questions concrete: who conducts the consultation, who makes the prescribing decision, and who can provide the final dispensing information? These are responsibilities to clarify, rather than roles this review has independently tested across the network.
A measured hormone is not a promised medicine
BodyLogicMD’s Advantage description promotes hormone panels and individualized care. A laboratory menu may name progesterone as something measured; that is not a promise to prescribe progesterone, nor does it identify a micronized product. A clinical interpretation and a treatment proposal are additional steps. This distinction also prevents a reader from treating a reported number as an instruction to obtain a particular capsule. The service’s emphasis on testing is its advertised approach, not comparative proof that a broader panel produces better outcomes. Questions about the purpose and limitations of a proposed test belong with the responsible clinician before it is purchased.
Bioidentical describes identity, while approval concerns the product
The network’s menopause language emphasizes bioidentical hormones. That term cannot tell a reader whether a proposed medicine is an approved manufactured product or a compound prepared for a prescription. FDA’s compounded-drug information describes the absence of premarket FDA approval for compounded drugs. The bioidentical approval guide explains why that regulatory distinction should not disappear behind an identity term. Conversely, recognizing a compound does not supply enough information to make a personal treatment decision. The selected clinician should explain what is proposed and why, including the relevant alternatives and the limits of the evidence for that preparation.
An ingredient question requires the actual manufacturer or pharmacy
The FDA’s generic-drug guidance explains that approved generics must meet requirements linking them to the reference medicine, while some inactive ingredients can differ. A network-wide phrase therefore cannot establish the excipients in a future prescription. The brand name, manufacturer and supplied product information may matter to a pharmacist addressing an ingredient concern. Our micronized guide likewise treats processing terminology as only one part of a description. It does not identify a capsule shell, filler, oil or allergy status. BodyLogicMD’s directory provides a clinical contact; it does not replace the preparation-specific information that contact and the dispensing pharmacy would need to provide.
The advertised $79 buys a membership category
The pricing page advertises Advantage starting at $79 per month, with month-to-month membership and cancellation language. It describes laboratory panels and treatment at member pricing, rather than establishing that all tests and medicines are included for $79. The distinction is substantial when comparing a recurring service payment with the cost of a prescription. The selected practice should identify what the membership includes, which appointments or tests create separate charges, and what cancellation changes about access. We did not establish a complete individual bill, a medicine price or personal insurance coverage. A promotional membership figure is not a quote for a specified amount of progesterone.
Natural-language claims need the same scrutiny elsewhere
Our Renew Youth review examines natural-hormone language and broad benefit statements. BodyLogicMD’s menopause offer raises a related issue: a reassuring category word can make the remaining formulation questions easy to overlook. The progesterone and progestin guide keeps medicine identities distinct without arranging them into a general safety ranking. Neither a professional network nor a familiar hormone term verifies a particular person’s expected outcome. Compare the specificity of the documents available, including the exact prescription information and who will explain it, rather than using the strongest promotional adjective as a deciding factor.
Bring the network, practice and medicine into one conversation
A focused inquiry would ask the selected BodyLogicMD practice to identify the professional responsible for treatment, the proposed preparation and the costs that sit outside membership. The directory and pricing description answer different parts of that inquiry and should remain separate until the practice supplies a personal plan. The clinician can address intended benefit, uncertainties and review arrangements; a pharmacist can check the exact supplied ingredients. This review confirms a menopause-care network and its published membership offer. It does not establish a uniform micronized progesterone catalog or endorse the network’s testing and treatment claims as evidence of clinical superiority.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- BodyLogicMD: MenopauseProvider menopause service and attributed testing or outcome claims; not comparative clinical evidence · Checked 2026-09-29
- BodyLogicMD: Find a bioidentical hormone doctorProvider network and access description; no individual provider availability or exact capsule confirmed · Checked 2026-09-29
- BodyLogicMD: PricingProvider membership and member-pricing terms; membership does not include every test or treatment · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- FDA: Generic Drugs — Questions & AnswersFDA public generic-drug explanation, updated September 18, 2026; approved-generic requirements and qualified inactive-ingredient differences, not identification or substitution advice for a particular provider prescription · Checked 2026-09-29